iPS Cells & Regenerative Medicine– category –
-
Sartorius and LFB BIOMANUFACTURING Broaden Partnership to Offer Integrated Cell Line Development-to-GMP Services
PharmaSource Global Overview Sartorius and LFB BIOMANUFACTURING have expanded their strategic collaboration to provide integrated services spanning cell line development to GMP drug substance manufacturing. This partnership aims to simpl... -
Minaris Expands GMP Cell Banking Capabilities in Philadelphia, Enhancing Cell & Gene Therapy CDMO Services
Contract Pharma USA Overview Minaris has significantly enhanced its GMP cell banking suite at its Philadelphia facility, expanding its cell and gene therapy (CGT) CDMO services. This upgrade enables comprehensive support for clinical and... -
Beam Therapeutics Gains FDA IND Approval for In Vivo Base Editing Therapy BEAM-304 for PKU
CRISPR Medicine News USA Overview Beam Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for BEAM-304, an in vivo base editing therapy targeting phenylketonuria (PKU). This therapy utilizes adenine base editing d... -
Automated Cell Therapy Manufacturing Lands $1.1 Billion Investment, Poised to Transform Commercialization and Patient Access
Tracxn (Indian Pharma Post経由) India Overview The automated cell therapy manufacturing sector has secured approximately $1.1 billion across 34 funding rounds, reflecting strong investor confidence and paving the way for scalable commerc... -
Tacit Knowledge Loss in Cell & Gene Therapy Tech Transfer Poses Critical Threat to Manufacturing Yield and Quality
Drug Discovery and Development USA Overview The transfer of cell and gene therapy manufacturing processes is severely hampered by the loss of tacit knowledge, impacting product yield and quality. Manual steps in CAR-T cell production, su... -
Genomic Engineering Strategies and Alternative Cell Types in Allogeneic T-Cell Immunotherapy Platforms Enable Scalable Cancer Treatment
Academic Publication Global Overview Allogeneic T-cell therapy is emerging as a highly promising strategy in cancer immunotherapy due to its scalability and 'off-the-shelf' availability, overcoming logistical and manufacturing constraint... -
Allogeneic CAR-T Cell Therapies Promise to Overcome Autologous Challenges and Expand Therapeutic Potential in Solid Tumors
PubMed (Review Article) Global Overview This review article details how allogeneic CAR-T cell therapies demonstrate clinical benefits in B-cell malignancies and offer the potential to overcome key limitations of autologous CAR-T, such as... -
UCLA Health Accelerates Cancer Therapy Screening with 3D Bioprinting and AI-Integrated Platform
UCLA Health Jonsson Comprehensive Cancer Center USA Overview UCLA Health Jonsson Comprehensive Cancer Center researchers have developed an innovative platform combining 3D bioprinting, advanced imaging, and AI to rapidly identify promisi... -
First Report of CRISPR-Derived Base Editing in Human Embryos Achieves Precise DNA Changes While Avoiding Large Chromosomal Aberrations
CMN Weekly (CRISPR Medicine News) Unknown Overview CRISPR-derived base editing has been successfully applied to human embryos for the first time, achieving precise DNA changes while circumventing the large chromosomal aberrations typical... -
Intellia Therapeutics’ In Vivo CRISPR Therapy Lonvo-z Achieves 87% Attack Rate Reduction in HAE Phase 3 Trial, Initiates Rolling BLA Filing with FDA
Intellectia.AI USA Overview Intellia Therapeutics' in vivo CRISPR therapy, lonvo-z, demonstrated an 87% reduction in hereditary angioedema (HAE) attack frequency in its Phase 3 HAELO trial. Following these breakthrough results, the compa...
